ATE393766T1 - Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen - Google Patents
Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungenInfo
- Publication number
- ATE393766T1 ATE393766T1 AT04715072T AT04715072T ATE393766T1 AT E393766 T1 ATE393766 T1 AT E393766T1 AT 04715072 T AT04715072 T AT 04715072T AT 04715072 T AT04715072 T AT 04715072T AT E393766 T1 ATE393766 T1 AT E393766T1
- Authority
- AT
- Austria
- Prior art keywords
- biaryltetrahydroisocinoline
- piperidines
- obesity
- treatment
- receptor antagonists
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45079903P | 2003-02-28 | 2003-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393766T1 true ATE393766T1 (de) | 2008-05-15 |
Family
ID=32962533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04715072T ATE393766T1 (de) | 2003-02-28 | 2004-02-26 | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7498441B2 (enExample) |
| EP (1) | EP1601664B1 (enExample) |
| JP (1) | JP4570165B2 (enExample) |
| CN (1) | CN1777596A (enExample) |
| AR (1) | AR043420A1 (enExample) |
| AT (1) | ATE393766T1 (enExample) |
| CA (1) | CA2517088A1 (enExample) |
| DE (1) | DE602004013427T2 (enExample) |
| ES (1) | ES2305735T3 (enExample) |
| MX (1) | MXPA05009193A (enExample) |
| TW (1) | TW200427679A (enExample) |
| WO (1) | WO2004078745A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2677096A1 (en) * | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| JP2011529062A (ja) | 2008-07-23 | 2011-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| WO2010011768A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| WO2010017350A1 (en) * | 2008-08-06 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Aminopyridine kinase inhibitors |
| EP2427464A1 (en) | 2009-05-06 | 2012-03-14 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines |
| CN102869663A (zh) | 2010-01-27 | 2013-01-09 | 沃泰克斯药物股份有限公司 | 吡唑并吡嗪激酶抑制剂 |
| EP2582702A1 (en) | 2010-01-27 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrimidine kinase inhibitors |
| MX2012008644A (es) | 2010-01-27 | 2012-11-23 | Vertex Pharma | Inhibidores de cinasa de pirazolopiridinas. |
| MX2018007844A (es) * | 2015-12-22 | 2019-01-21 | Jiangsu Hengrui Medicine Co | Derivado de benzopiperidina, metodo de preparacion del mismo y su uso medico del mismo. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| KR100589872B1 (ko) * | 1997-05-30 | 2006-06-15 | 뉴로서치 에이/에스 | 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법 |
| EP1113007A1 (en) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| JP2004504303A (ja) * | 2000-07-05 | 2004-02-12 | シナプティック・ファーマスーティカル・コーポレーション | 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用 |
| JP4280073B2 (ja) | 2001-04-12 | 2009-06-17 | ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド | Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン |
| JP4522853B2 (ja) * | 2002-06-27 | 2010-08-11 | シェーリング コーポレイション | 肥満の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしてのスピロ置換ピペリジン |
-
2004
- 2004-02-26 CN CNA2004800109047A patent/CN1777596A/zh active Pending
- 2004-02-26 TW TW093104942A patent/TW200427679A/zh unknown
- 2004-02-26 US US10/788,109 patent/US7498441B2/en not_active Expired - Fee Related
- 2004-02-26 DE DE602004013427T patent/DE602004013427T2/de not_active Expired - Lifetime
- 2004-02-26 EP EP04715072A patent/EP1601664B1/en not_active Expired - Lifetime
- 2004-02-26 CA CA002517088A patent/CA2517088A1/en not_active Abandoned
- 2004-02-26 MX MXPA05009193A patent/MXPA05009193A/es active IP Right Grant
- 2004-02-26 JP JP2006508855A patent/JP4570165B2/ja not_active Expired - Fee Related
- 2004-02-26 AT AT04715072T patent/ATE393766T1/de not_active IP Right Cessation
- 2004-02-26 WO PCT/US2004/005780 patent/WO2004078745A1/en not_active Ceased
- 2004-02-26 ES ES04715072T patent/ES2305735T3/es not_active Expired - Lifetime
- 2004-02-27 AR ARP040100622A patent/AR043420A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2517088A1 (en) | 2004-09-16 |
| US7498441B2 (en) | 2009-03-03 |
| JP2006520399A (ja) | 2006-09-07 |
| CN1777596A (zh) | 2006-05-24 |
| MXPA05009193A (es) | 2005-10-18 |
| AR043420A1 (es) | 2005-07-27 |
| TW200427679A (en) | 2004-12-16 |
| EP1601664B1 (en) | 2008-04-30 |
| WO2004078745A1 (en) | 2004-09-16 |
| DE602004013427D1 (de) | 2008-06-12 |
| EP1601664A1 (en) | 2005-12-07 |
| DE602004013427T2 (de) | 2009-06-04 |
| ES2305735T3 (es) | 2008-11-01 |
| US20040176355A1 (en) | 2004-09-09 |
| JP4570165B2 (ja) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE410161T1 (de) | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen | |
| DE60234116D1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems | |
| ATE302185T1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| ATE519488T1 (de) | Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten | |
| DE60317631D1 (de) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie | |
| DE60221569D1 (de) | Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen | |
| ATE432924T1 (de) | 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten | |
| ATE448206T1 (de) | Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen | |
| DE602004029833D1 (de) | VEGF-Fallen und therapeutische Verwendungen dafür | |
| IL156495A0 (en) | Use of fgfr3 antagonists for treating t cell mediated diseases | |
| ATE407927T1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
| ATE371451T1 (de) | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie | |
| EP1742675A4 (en) | TREATMENT OF BIOMEDICAL WASTE | |
| DE60212146D1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
| DE502004011551D1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen | |
| ATE393766T1 (de) | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen | |
| MX2007004306A (es) | Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados. | |
| ATE328880T1 (de) | Tetrazolderivate und verfahren zur behandlung von stoffwechselbedingten erkrankungen damit | |
| DE60307289D1 (de) | Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit | |
| DE602004022035D1 (de) | Verwendung von pthalide derivativen zur behandlung | |
| ATE499147T1 (de) | Zusammensetzungen und verfahren zur behandlung kognitiver störungen | |
| DE602006010737D1 (de) | 3-(4-äÄ4-(4äÄ3-(3,3-DIMETHYL-1-PIPERIDINYL)PROPYLÄOXYÜPHINYLÜ-1-PIPERIDINYLCARBONYLü-1-NAPHTHALINYL)PROPAN- ODER PROPENSÄURE ALS H1- UND H3-REZEPTOR-ANTAGONISTEN ZUR BEHANDLUNG ENTZÜNDLICHER UND/ODER ALLERGISCHER ERKRANKUNGEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |